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ABSTRACT 
To combat a variety of liver ailments medicinal plants may serve as a vital source because of presence of pharmacologically active 
phytoconstituents. It is very interesting to note that there is no drug available in the modem system of medicine for treating hepatic disorders; 
only certain herbal preparations are available to treat this quite vulnerable disease. A large number of plants with hepatoprotective activity are 
present but only handful of herbs have such scientific support. Herbal medicines have been used to alleviate liver disorders for many centuries 
and have currently become a favorable therapy for pathological liver disease. 
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INTRODUCTION 
In the beginning of modern medicine, biologically active 
agents from plants have played essential role in providing 
medicine to combat diseases. Medicines derived from plants 
continue to occupy an important corner in the treatment of 
disease worldwide1. In traditional or folk medicine the 
practices, ideas, beliefs and knowledge not based on 
scientific evidence is applied to treat, diagnose and prevent 
disease within a society. It is outlined by culture’s knowledge 
and beliefs and thus is context specific, as are social 
constructions and negotiations of risk. Modern society when 
adopts such long existing practices outside of their 
traditional circumstances, these practices become 
supportive, alternative or non conventional medicine2. With 
such traditional practice modern medicine may exist side by 
side, herbal medicines have often continued their popularity 
for cultural and past reasons. In developed countries such 
products have become more widely available commercially. 
In this modern setting, ingredients are sometimes marketed 
for uses that were never contemplated in the traditional 
healing systems from which they emerged. An example is the 
use of ephedra (Ma huang) for weight loss or athletic 
performance enhancement3. In poor communities traditional 
medicine has remained the easily approachable and most 
affordable source of treatment in the primary health care 
system. The medicinal use of plants is very old4. The system 
of ethno-medicine is safe and is a low cost therapy for 
treating various ailments. Herbal medicines have been 
widely used and formed an integral part of primary health 
care in India, China, Ethiopia, Argentina and Papau and New 
Guinea5. Traditional Medicines like Ayurvedic, Siddha and 
Unani are predominantly plant based. Herbal drugs have 
gained importance and popularity in recent years because of 
their safety, efficacy and cost effectiveness6. According to 
World Health Organization (WHO), ethno medicine has 
retained its reputation in all regions of the developing world 
and its use is rapidly growing in the industrialized countries. 
Traditional herbal remedies account for 30-50% of the total 
medicinal consumption in China7. In Ghana, Nigeria and 
Zambia, the first line treatment for 60% of the children with 
malaria is the use of herbal medicine7.With minimum side 
effects and low cost, people in developing countries like 
Bangladesh (90%), Myanmar (85 %), India (80%), Nepal 
(75%), Sri Lanka (65%) and Indonesia (60%) have strong 
belief in this system of medicine8. 
LIVER 
The largest and most complex internal organ in the body is 
liver. With the help of its multifarious and several functions, 
it plays an important role in maintenance of internal 
environment. Liver is involved in metabolism of fats, 
carbohydrates and fats in addition liver synthesis number of 
plasma proteins such as fibrinogen, albumin and in the 
production of various enzymes, formation and excretion of 
bile. Some prevalent liver disease is given below: 
 Acute liver disease: the patient is deemed to have acute 
liver disease if the onset of symptoms does not exceed 
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six months. Most cases are self-limiting episodes of 
hepatocyte inflammation or damage, which settle 
without causing further complications. In some rare 
cases the damage is so severe that it affects the whole 
liver leading to acute liver failure. Such rare cases are 
involved with a high mortality and may require liver 
transplantation.  
 Chronic liver disease: symptoms of liver disease that 
persist for more than six months causes chronic liver 
disease. It occurs when permanent structural changes 
within the liver occur secondarily to longstanding 
hepatocyte damage9. 
 Drug-induced liver injury is a major health problem that 
objects not only health care persons but also 
pharmaceutical industry and drug regulatory agencies. 
According to the United States Acute Liver Failure study 
group, more than 50% of acute liver failure is due to 
drug-induced liver injury, including hepatotoxicity 
caused by overdose of acetaminophen (39%) and 
idiosyncratic liver injury triggered by other drugs 
(13%)9. Liver diseases accounts for morbidity and 
mortality in man and animals all over globe and 
hepatotoxicity due to drug appears to be the most 
common contributing factors10. 
 Hepatitis can be caused by the, mushrooms, parasite 
like amoebas or giardiasis, drugs, viruses, bacteria. Viral 
hepatitis is caused by infection with any of at least five 
distinct viruses, of which the three most commonly 
identified are hepatitis A virus (HAV), hepatitis B virus 
(HBV), and hepatitis C virus (HCV)11.In India about 40 
poly herbal commercial formulations reputed to be 
active against liver diseases are being used. From 101 
plants having hepatoprotective activity 160 phyto 
constituents have been reported12.Liver protective 
herbal drugs contain a variety of chemical constituents 
like phenols, coumarins, lignans, essential oil, 
monoterpenoids, carotenoids, glycosides, and xanthines. 
Plant extracts of many crude drugs are also used for the 
treatment of liver disorders. 
 Nonalcoholic fatty liver disease (NAFLD) presents a 
spectrum of disorders characterized by the 
accumulation of fat in the liver. This spectrum covers 
simple steatosis and lobular inflammation with variable 
degrees of fibrosis leading to cirrhosis and even 
hepatocellular carcinoma (HCC)13. It is strongly 
associated with the metabolic syndrome and is the 
leading cause of chronic liver disease worldwide, with a 
prevalence of 15%–30% in Western populations14. 
 Liver fibrosis has emerged as a major health problem. It 
is the outcome of sustained wound healing response to a 
chronic liver injury from a variety of causes including, 
drug induced, viral, metabolic diseases and autoimmune 
cholestatic. In Hepatic fibrosis there is immoderate 
production and deposition of extracellular matrix 
(ECM)15, 16. 
Hepatic disorders are extreme pain in right shoulder, ribs 
and right leg, stiffness in the right arm, discoloration of stool, 
nausea, yellow-blood like urine, anorexia, jaundice, and 
heartburns. All these can lead to liver abscess. Jaundice is 
mainly due to pitta dosha and the symptoms are yellowish 
color of eyes, skin, nails, face and urine, faded skin color like 
that of a frog, impaired senses, burning pain in the 
epigastrium, indigestion, asthenia and anorexia17. 
 
HERBAL DRUGS AS A THERAPHY FOR LIVER 
DISEASES 
The Indian Traditional Medicine like Siddha, Unani and 
Ayurvedia are predominantly based on the use of plant 
materials. Because of safety, efficacy and cost effectiveness of 
herbal drugs have gained importance and popularity in 
recent years. Several Indian medicinal plants have been 
extensively used in the Indian traditional system of medicine 
for the management of liver disorder. Scientific evaluation of 
plants has often shown that active principles in these are 
responsible for therapeutic success. In spite of the 
phenomenal advances in biochemical, therapeutic and 
cellular approaches to many diseases, liver diseases remain 
confusing today. Liver diseases are among the important 
diseases affecting humans, there is a lack of effective 
remedies to treat them satisfactorily. None of the available 
preparations are specific for liver disorders. In India the 
indigenous system of medicine has abundant data on drugs 
available for the treatment of liver disorders. For centuries 
these drugs have been used and have claimed to offer 
remarkable relief.  
For a wide variety of liver disorders several hundred plants 
have been examined. Just handfuls have been fairly well 
researched. 
1. Silybum marianum:  
 Since the 16th century (Milk thistle) has been used to treat 
liver diseases. Its major constituents are the flavonoids; 
silibinin, silidianin, silichristin, and isosilibinin of which 
silibinin is the biologically most active compound and used 
for standardization of pharmaceutical products18. Silymarin 
is a strong antioxidant that promotes liver cell regeneration, 
reduces blood cholesterol, and helps in preventing cancer19. 
A number of well-designed experimental studies suggest that 
through antifibrotic properties silymarin might exert 
beneficial effects in chronic liver diseases. For example, 
silymarin interferes with leukotriene formation in Kupffer 
cell cultures and may thereby inhibit hepatic stellate cell 
(HSC) activation, which is a crucial event in fibrogenesis20. In 
alcoholic and non-alcoholic fatty liver and steatohepatitis, 
drug and chemically-induced hepatic toxicity caused by 
oxidative stress the antioxidant medicine silymarin is the 
primary therapeutic modality of choice21.As a result of its 
anti-inflammatory, immunomodulating antioxidative, anti-
lipid-peroxidative, antifibrotic, and even liver regenerating 
effects it has been claimed that silymarin has clinical 
applications in the treatment of cirrhosis, ischaemic injury, 
radiation toxicity toxic hepatitis, viral hepatitis and fatty 
liver22. The marketed preparations of silymarin are capsules 
or tablets containing ethanol extracted silymarin in amounts 
of 250–750 mg, and purported to be beneficial for liver 
diseases. It is typically taken 2–3 times daily but daily dosage 
varies. In Europe Intravenous preparations of purified 
Silybinin are approved for therapy of Amanita phalloides 
mushroom poisoning23. 
2. Camellia sinensis (Green Tea): 
An inherent herb from southern China is made from the 
leaves of the plant Camellia sinensis. Green tea is composed 
of active compounds such as catechin, gallocatechin, 
epicatechin, epigallocatechin, epicatechingallate, and 
epigallocatechingallate (EGCG) in which EGCG is considered 
the most therapeutically significant compound. Apart from 
the use of green tea in acute liver injury and oxidative stress 
injury, green tea is proved to be useful in preventing Hepatic 
C Virus (HCV) entry into the liver cells24. Many studies have 
shown that the polyphenolic fractions isolated from green 
tea possess anti-inflammatory activity and inhibit oxidant 
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stress25. In animal models they have been reported to 
prevent liver toxicity induced by a number of 
hepatotoxicants like: carbon tetrachloride, acetaminophen 
and 2-nitropropane. In both diet induced and genetic animal 
model dietary green tea has also been shown to prevent fatty 
liver disease26. 
3. Andrographis paniculata  
In Indian systems of medicine it is extensively used as 
hepatoprotective and hepatostimulant agent27.Very few 
studies on the effects of crude extracts of A. paniculata on 
liver function are available. Most studies for hepatic effects 
have been conducted on either andrographolide or other 
purportedly active principles. Significant choleretic effects of 
andrographolide in anesthetized guinea pigs and in 
conscious rats have been reported. Protection of 
andrographolide against acetaminophen-induced reduction 
in volume and contents of bile was better than that produced 
by silymarin28.  
4. Glycyrrhiza glabra 
It has been used in traditional medicine to alleviate 
bronchitis, gastritis and jaundice and is obtained from 
aqueous extract of the liquorice root (Glycyrrhiza glabra). 
The major constituents are hydroxycoumarins, flavonoids, 
glycyrrhetic acid and beta-sitosterol, the latter with probable 
glucocorticoid and mineralocorticoid properties. An 
established treatment for chronic hepatitis in Japan is a 
standardised extract containing glycyrrhizin, cysteine and 
glycine.A daily dose of 80 mg/day given intravenously for 2 
weeks normalised elevated aspartate and alanine 
transaminase29. This prepration is also available over-the-
counter in the United States as a, powder, tablet and tablet. 
The protection against various forms of experimental hepatic 
injury is due to inhibition of activity of 11-beta-
hydroxysteroid dehydrogenase, prostaglandin E2 production 
by macrophages, and antioxidant properties through the 
induction of catalase and glutathione-S-transferases30. Some 
evidence points to an antifibrotic effect in the rat CCl4 model; 
possibly through inactivation of NFκB31.In an open-label trial 
including 56 patients with subacute liver failure Glycyrrhizin 
has also been used. Patients were treated for 30 days with 
glycyrrhizin 100 ml daily followed by an 8-week period with 
glycyrrhizin administration every other day. With historical 
controls from the previous 10 years survival was compared 
and proved to be better in the glycyrrhizin-treated group32. 
However, the design of this study does not allow clear 
conclusions with regard to the usefulness of glycyrrhizin in 
the treatment of advanced liver disease. 
      5. Phyllanthus amarus  
The plants of the genus Phyllanthus have long been used to 
treat chronic liver diseases and are found in most tropical 
and subtropical countries. Several polyphenoles, 
hypophyllantins and Phyllantins are major constituents of 
which chemical and pharmacological properties are well 
described33. Experimental data indicate through interference 
with polymerase activity, mRNA transcription and 
replication some of the active compounds within Phyllanthus 
may exert activity against hepatitis B virus infection34. 
6. Liv-52. 
Recognized and registered in more than 45 countries, an 
Ayurvedic supplement, and a well-known herb prescribed by 
many physicians worldwide. Introduced in 1955, Liv-52 has 
been studied since then for the treatment of liver diseases 
such as fatty liver conditions, protein energy malnutrition, 
alcohol liver disease, pre-cirrhotic hepatitis, and early 
cirrhosis conditions, elevated liver enzymes, radiation or 
chemotherapy-induced liver damage35. Liv-52 contains the 
following herbs: Terminalia  arjuna, Cassia occidentalis 
Capparis  spinosa, Cichorium  intybus, Solanum  nigrum, and 
Phyllanthus amarus and is available as tablets and syrup36.   
According to the manufacturers, during the process there is 
contact of the ingredients which could result in both 
individual and collective action on the liver. Apart from 
occasional complaints of nausea, Liv-52 has not shown any 
serious side-effects.  
7. Ocimum sanctum 
Ocimum sanctum L. (Labiatae; popularly known as “Tulsi” in 
Hindi and “Holy Basil” in English) .In various traditional and 
folk systems of medicine, including traditional Chinese 
medicine, Roman, Siddha, Ayurveda, Unani and Greek Tulsi is 
known herb which is an important hepatoprotective plant37. 
The various activities of analgesia, hepatoprotection, 
hypolipidemia, immunomodulation, anti-diabetes, anti-
inflammation, antipyresis, anti-neoplasia and antistress is 
due to presence of many important phytochemicals38. For 
the treatment of liver diseases, some studies have shown 
that the combination use of holy basil and silymarin 
demonstrated synergistic hepatoprotective activity. 
PHYTOCONSTITUENTS FROM PLANTS HAVING 
HEPATOPROTECTIVE POTENTIAL 
Several chemically defined molecules have been isolated 
from crude plant extracts with proven hepatoprotective 
activity. A list of these compounds is shown in Table 1 with 
information on family and part of plants used. 
 
Table 1: Phytoconstituents from plants having hepatoprotective potential 
Phytoconstituents Scientific name Common 
name 
Family Part used Ref 
 
Silymarin Silybum marianum Milk thistle Asteraceae Ripen seeds 39 
Andrographolide and 
neoandrographolie 
Andrographis paniculata Bhuinimb Acanthaceae Leaves & tender shoot 40 
Curcumin  Curcuma turmeric Zingiberaceae rhizomes 41 
Picroside and kutkoside Picrorrhiza kurroa Kutki Srophulariaeae  Dried rhizomes 42 
coumarinolignoids, 
cleomiscosins A, B, and C 
Cleome viscosa tick weed Capparidaceae seeds 43 
Oleanolic acid 
triterpenic aci d 
Lantana camara big-sage Verbenaceae weed 44  
Ursolic acid Ocimum basilicum Basil Lamiaceae leaves 44 
Berberine   Berberis aristata Chutro Berberidaceae roots, rhizomes and stembark 45 
Saikosaponin C, 
Saikosaponin b2 
 Bupleurum marginatum 
Wall. ex 
Jangli zeera Apiaceae root 46 
Beta-elemene Curcuma aromatica Salisb Wild turmeric zingiberaceae Root and rhizome 47 
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Ombuine Gynostemma pentaphyllum Sweet tea cucurbitaceae Whole plant 47 
Wogonin Scutellaria baicalensis   Baikal skullcap lamiaceae roots 48 
Monomethyl fumarate Fumaria indica  fumitory fumariaceae Whole plant 49 
Kinsenoside Anoectochilus formosanus 
Hayata 
 orchidaceae Whole plant 50 
Acanthoic acid  Acanthopanax koreanum 
Nakai 
 araliaceae Root bark 51 
Indigtone  Indigofera tinctoria L. neel fabaceae Aerial parts 52 
Anastatin A  Anastatica hierochuntica  brassicaceae Whole plant 53 
Anastatin B Anastatica hierochuntica  Brassicaceae Whole plant 53 
 
These compounds can serve as important leads, for the 
discovery of new drugs in the treatment of liver diseases. 
However, for many of these compounds, the clinical data are 
very limited. Clinical efficacy and potential toxicity of active 
compounds in larger trials requires further assessment, 
before recommendations concerning their routine use can be 
identified.  
CONCLUSION 
The current review provides a detailed and updated 
description of the most widely used herbal medicine in 
treatment of chronic liver disease. Herbal drugs can treat 
various liver ailments by inhibiting oxidative damage, 
suppressing fibrogenesis, eliminating virus infection, and 
preventing or inhibiting tumor growth. Herbal medicine has 
become a major contributor to the treatment of liver 
diseases. The future of the treatment of liver diseases with 
herbal medicines depends on our understanding of each and 
every chemical compound and their interactions with each 
other. Currently, a handful of herbal drugs, such as 
Glycyrrhiza glabra, Silymarin and Liv52, have been studied 
thoroughly. These drugs and the other drugs mentioned in 
the presented study have shown the scientific community 
their significance and possible usage as major treatment 
modalities for liver diseases. 
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